Kyntra Bio, Inc.

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California, with a virtual office address at 350 Bay St, Ste 100 #6009, San Francisco, CA 94133. The company's mission is to advance the development of innovative treatments at the frontiers of cancer biology and rare diseases.

Kyntra Bio's pipeline focuses on oncology and rare disease therapies. Key product candidates include roxadustat, which is being evaluated for anemia associated with lower-risk myelodysplastic syndrome (LR-MDS), and FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 for metastatic castration-resistant prostate cancer (mCRPC). The company also develops FG-3180, a companion PET imaging agent for FG-3246.

Formerly known as FibroGen, Inc., the company rebranded to Kyntra Bio on January 8, 2026, and began trading under the new NASDAQ ticker symbol KYNB, signaling a sharpened strategic focus on oncology and rare diseases. Thane Wettig serves as the Chief Executive Officer, and David DeLucia is the Chief Financial Officer. Recent corporate actions include the sale of its Chinese subsidiary, FibroGen China, in 2025, and the extension of its cash runway into 2028. Roxadustat has received FDA Orphan Drug Designation for myelodysplastic syndromes.